Moleculin Biotech, Inc. (MBRX) stock
MBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.75−0.08 (-1.17%)
Close on Nov 18, 2026Market cap $131.47MP/E –Yield –
Moleculin Biotech free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Moleculin Biotech's free cash flow for the twelve months ending Dec 31, 2025 was -$22.74M. For fiscal 2025 it was -$22.74M. The highest annual figure on record is -$3.79M in fiscal 2016.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$22.74M | – |
| FY2024 | Dec 31, 2024 | -$23.88M | – |
| FY2023 | Dec 31, 2023 | -$23.72M | – |
| FY2022 | Dec 31, 2022 | -$27.71M | – |
| FY2021 | Dec 31, 2021 | -$18.97M | – |
| FY2020 | Dec 31, 2020 | -$18.15M | – |
| FY2019 | Dec 31, 2019 | -$17.25M | – |
| FY2018 | Dec 31, 2018 | -$12.62M | – |
| FY2017 | Dec 31, 2017 | -$7.35M | – |
| FY2016 | Dec 31, 2016 | -$3.79M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$5.37M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.22M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.58M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.56M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.08M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.11M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.96M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.72M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.98M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.58M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.14M | – |
| Q1 FY2023 | Mar 31, 2023 | -$6.02M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.26M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.58M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.06M | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.81M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.28M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.29M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.78M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.62M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.14M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.71M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.95M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.34M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.69M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.34M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.37M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.86M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.22M | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.11M | – |
| Q2 FY2018 | Jun 30, 2018 | -$3.47M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.82M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.41M | – |
| Q3 FY2017 | Sep 30, 2017 | -$1.62M | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.18M | – |
| Q3 FY2016 | Sep 30, 2016 | -$961.00K | – |
See a number that looks wrong?